Mathematical models and computer simulations can open the possibility of pre-assessment for drug and vaccine efficacy against the virus.
Computer models are used to simulate COVID-19 infections on a cellular level, which will allow for virtual trials of drugs and vaccines, opening the possibility of pre-assessment for drug and vaccine efficacy against the virus. The research team at the University of Waterloo includes Anita Layton, professor of applied mathematics and Canada 150 Research Chair in mathematical biology and medicine, and Mehrshad Sadria, an applied mathematics PhD student.
‘In silico trials may soon replace Clinical trials, which are expensive and can cost human lives.’
Read More..
In silico experiments were used to replicate how the human immune system deals with the COVID-19 virus. Read More..
"It's not that in-silico trials should replace clinical trials," Layton said.
"A model is a simplification, but it can help us whittle down the drugs for clinical trials. Clinical trials are expensive and can cost human lives. Using models helps narrow the drug candidates to the ones that are best for safety and efficacy."
Researchers captured the results of different treatments that were used on COVID-19 patients in clinical trials. Their results are remarkably consistent with live data on COVID infections and treatments.
The simulated model and the live trial both showed Remdesivir to be biologically effective but clinically questionable, unless administered shortly after viral infection.
Advertisement
"As we learn more about different variants of concern, we can change the model's structure or parameters to simulate the interaction between the immune system and the variants," Sadria said. "And we can then predict if we should apply the same treatments or even how the vaccines might work as well."
Advertisement
Source-Medindia